385MO A multicenter, open-label, dose escalation and expansion study of DP303c in patients with HER2-positive pre-treated advanced solid tumors

DP303c is a HER2-targeting ADC with a cleavable linker-MMAE payload. Pre-clinical study demonstrated similar to or better antitumor activity than T-DM1 in xenograft models. Here we present the safety and efficacy of DP303c in patients (pts) with HER2-positive pre-treated advanced solid tumors.